CLYM•benzinga•
Climb Bio Enters Exclusive License Deal With Mabworks For Rights To Develop, Commercialize MIL116 (Now CLYM116) Monoclonal Antibody, In Territory Outside China
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga